Roche reports strong 2024 results with 7% (CER) sales growth; fourth quarter marks third straight quarter of 9% growth. 👉 Read the full release here: $ROG $RHHBY #FinancialResults

Roche continues strong momentum with 7% growth (CER) in the first half of 2025 – full-year outlook confirmed. For more details on our performance, click here ➡️ . $ROG $RHHBY #RocheFinancialResults

#MEDIA — We are pleased to announce that the European Commission has approved our medicine for PIK3CA-mutated, ER-positive, HER2-negative, advanced #BreastCancer, helping to address an urgent unmet need. $ROG $RHHBY

#MEDIA - We’re pleased to announce we have received CE mark for our blood test to rule out Alzheimer’s disease. This minimally invasive test can reduce the need for additional confirmatory investigations. . $RHHBY $ROG

The answer is all of the above!. Mass spectrometry enables better patient care through unparalleled specificity and accuracy. Find out how Roche is shaping the future of clinical diagnostics here:

Mass spectrometry has the potential to provide patients with more personalised diagnoses. But do you know what makes this technology a gold standard in clinical diagnostic testing? . Select your answer below. #massspectrometry #innovation #diagnostics #RocheMassSpec.

Next-generation sequencing (NGS) plays an essential role in understanding the genetics of complex diseases. At Roche, we are leading the way with our breakthrough technology, sequencing by expansion (SBX). Discover how SBX is revolutionizing genomics:

We're proud to renew our collaboration with The Global Fund to strengthen lab systems and diagnostics services that are essential for equitable access to care. Together, we leverage our expertise, resources and network to maximize our impact in low and middle-income countries.

#MEDIA We’re please to share that Phase I/II data presented at #ISTH2025 show that our investigational bispecific antibody may have the potential to provide haemostatic normalization in people with haemophilia A.

We’re expanding affordable pricing for HPV DNA testing to support critical screening for an additional 50 million women living in LMICsUp. . #CervicalCancerElimination #GlobalHealth #HPVTesting #Roche

#MEDIA – We're pleased to share new late-breaking data at #18ICML, showing that our investigational combination treatment could offer people with aggressive #lymphoma a well-tolerated option without traditional chemotherapy. $RHHBY $ROG

Pharma and academia play distinct but complementary roles in driving innovation. In a new @Nature article, @HansClevers shares insights on how bridging both worlds can accelerate progress in healthcare. Read more here:

#MEDIA —We are advancing our investigational anti-alpha-synuclein antibody into Phase III development for early-stage #ParkinsonsDisease $ROG $RHHBY

Antimicrobial resistance (AMR) is a pressing reality. The WHO projects that AMR could cause up to 10 million deaths annually by 2050 if current trends continue. Let's take action now to ensure life-saving medicines remain effective for future generations.

#MEDIA – We are pleased our Phase III data at #ASCO25, published in #TheLancet, show survival benefits for people with small cell #lungcancer. SCLC is an aggressive cancer type where more options for disease control are highly needed: $ROG $RHHBY

#MEDIA We are very encouraged about the Phase III data being presented at #ASCO25 by @Alliance_org in #coloncancer. Huge thanks to Alliance, the investigators and patients taking part in this study. $ROG $RHHBY

#MEDIA — We are pleased to be presenting new overall survival data at #ASCO25 for our medicine in people with advanced PIK3CA-mutated, HR-positive, HER2-negative #BreastCancer, supporting standard of care potential. .$ROG $RHHBY

#MEDIA — New 96-week data shows maintained near-complete suppression of disease activity and no disability progression for up to two years in people with relapsing multiple sclerosis. #MultipleSclerosis #ClinicalTrials . $ROG $RHHBY

At Roche, we're committed to combating AMR with scientific collaboration and innovative diagnostics and treatments. We're at the forefront of scientific collaboration to improve patient access to the latest innovations. #AMR #AntibioticResistance #RocheAMR

Our world is moving toward faster, personalized diagnostics. Next-generation sequencing (NGS) leads the way by uncovering the genetics of complex diseases. At Roche, we're advancing NGS with our innovative sequencing by expansion (SBX) technology. Learn more:

#MEDIA — We are pleased to announce a positive CHMP opinion for our medicine in advanced PIK3CA-mutated, ER-positive, HER2-negative #BreastCancer, an aggressive subtype of breast cancer associated with a poor prognosis. $ROG $RHHBY